Latest Breaking News On - Mesoblast limited nasdaq - Page 2 : comparemela.com

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSteve dabkowskiPaul hughesSilviu itescuPharmaceuticals coCorporate communications investorsMesoblast limited nasdaqDrug administrationResearch developmentMarrow transplant clinical trials networkNational institutes of healthAustralian securities exchangeMesoblast the companyChief executive silviu itescuUnited states food

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiSilviu itescuPaul hughesMesoblast limited nasdaqMesoblast the companyAustralian securities exchangeDrug administrationDrug designation programCorporate communications investorsJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiSilviu itescuPaul hughesDrug administrationCorporate communications investorsAustralian securities exchangeMesoblast the companyDrug designation programMesoblast limited nasdaqJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

Mesoblast Limited (MESO) Announces FDA Granted Orphan-Drug Designation for Revascor

Mesoblast Limited (MESO) Announces FDA Granted Orphan-Drug Designation for Revascor
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSilviu itescuDrug administrationMesoblast limited nasdaqMesoblast limitedUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPaul hughesSilviu itescuSteve dabkowskiMarrow transplant clinical trials networkAustralian securities exchangeCorporate communications investorsPharmaceuticals coProgram in chronic heart failureNational institutes of healthMesoblast limited nasdaqProgram in pediatric congenital heart diseaseChief executive silviu itescuRare pediatric diseaseHost disease